ICD Stock Overview
Intercapital Property Development ADSIC operates as a special purpose real estate investment trust (REIT) for real estate securitization in Bulgaria.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Intercapital Property Development ADSIC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | лв1.91 |
| 52 Week High | лв1.94 |
| 52 Week Low | лв1.16 |
| Beta | 1.07 |
| 1 Month Change | -1.55% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -3.05% |
| 5 Year Change | 1,064.63% |
| Change since IPO | -76.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| ICD | PL REITs | PL Market | |
|---|---|---|---|
| 7D | -1.5% | -0.8% | -0.8% |
| 1Y | n/a | -4.8% | 25.9% |
Return vs Industry: Insufficient data to determine how ICD performed against the Polish REITs industry.
Return vs Market: Insufficient data to determine how ICD performed against the Polish Market.
Price Volatility
| ICD volatility | |
|---|---|
| ICD Average Weekly Movement | n/a |
| REITs Industry Average Movement | 2.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in PL Market | 9.7% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: ICD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ICD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Velichko Klingov | icpd.bg |
Intercapital Property Development ADSIC operates as a special purpose real estate investment trust (REIT) for real estate securitization in Bulgaria. Its investment projects include Marina Cape and Grand Borovetz. The company has elected to be taxed as REIT under the Internal Revenue Code.
Intercapital Property Development ADSIC Fundamentals Summary
| ICD fundamental statistics | |
|---|---|
| Market cap | zł43.09m |
| Earnings (TTM) | zł1.27m |
| Revenue (TTM) | zł33.24m |
34.0x
P/E Ratio1.3x
P/S RatioIs ICD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICD income statement (TTM) | |
|---|---|
| Revenue | лв14.99m |
| Cost of Revenue | лв8.30m |
| Gross Profit | лв6.69m |
| Other Expenses | лв6.12m |
| Earnings | лв572.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | 0.021 |
| Gross Margin | 44.64% |
| Net Profit Margin | 3.81% |
| Debt/Equity Ratio | 39.8% |
How did ICD perform over the long term?
See historical performance and comparison